<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JCN</journal-id>
<journal-id journal-id-type="hwp">spjcn</journal-id>
<journal-id journal-id-type="nlm-ta">J Child Neurol</journal-id>
<journal-title>Journal of Child Neurology</journal-title>
<issn pub-type="ppub">0883-0738</issn>
<issn pub-type="epub">1708-8283</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0883073812443005</article-id>
<article-id pub-id-type="publisher-id">10.1177_0883073812443005</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Antiepileptic Drugs and Bone Metabolism in Children</article-title>
<subtitle>Data from 128 Patients</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Borusiak</surname>
<given-names>Peter</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0883073812443005">1</xref>
<xref ref-type="corresp" rid="corresp1-0883073812443005"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Langer</surname>
<given-names>Thorsten</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0883073812443005">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Heruth</surname>
<given-names>Marion</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-0883073812443005">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Karenfort</surname>
<given-names>Michael</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff3-0883073812443005">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bettendorf</surname>
<given-names>Ulrich</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff4-0883073812443005">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jenke</surname>
<given-names>Andreas CW</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0883073812443005">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0883073812443005"><label>1</label>Department of Pediatrics, HELIOS Hospital Wuppertal, Witten/Herdecke University, Faculty of Health, School of Medicine, Wuppertal, Germany</aff>
<aff id="aff2-0883073812443005"><label>2</label>Department of Pediatrics, HELIOS Hospital Borna, Borna, Germany</aff>
<aff id="aff3-0883073812443005"><label>3</label>Department of Pediatrics, University Hospital Düsseldorf, Düsseldorf, Germany</aff>
<aff id="aff4-0883073812443005"><label>4</label>KiPraHi, Hirschaid, Germany</aff>
<author-notes>
<corresp id="corresp1-0883073812443005">Peter Borusiak, MD, Department of Pediatrics, Helios Hospital Wuppertal, Witten/Herdecke University, Faculty of Health, School of Medicine, Heusnerstr 40, D-42283 Wuppertal, Germany. Email: <email>peter.borusiak@helios-kliniken.de</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2013</year>
</pub-date>
<volume>28</volume>
<issue>2</issue>
<fpage>176</fpage>
<lpage>183</lpage>
<history>
<date date-type="received">
<day>7</day>
<month>2</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>1</day>
<month>3</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>There are conflicting results concerning bone metabolism in children receiving antiepileptic medication, with data concentrating on neurologically impaired patients. We performed a multicenter cross-sectional study in otherwise healthy children who received monotherapy with valproic acid, oxcarbazepine, lamotrigine, sulthiame, levetiracetam, or topiramate for at least 6 months. Data on calcium, phosphorus, alkaline phosphatase, 25-OH vitamin D, and parathormone were collected. Among 128 patients, 24.4% had hypocalcemia, 25.4% hypophosphatemia, and 13.3% (n = 17) 25-OH vitamin D levels &lt;10 ng/mL. All patients were clinically asymptomatic. Mean calcium concentrations were found to be significantly lower among the study population (2.41 mmol/L) compared with healthy controls (2.53 mmol/L). Lowest mean concentration was observed in patients treated with sulthiame followed by oxcarbazepine and valproic acid. No influence of calcium intake or therapy on bone metabolism was noted. Effects on bone metabolism of anticonvulsive monotherapy are not restricted to neurologically impaired children but also affect otherwise healthy children.</p>
</abstract>
<kwd-group>
<kwd>epilepsy</kwd>
<kwd>osteopenia</kwd>
<kwd>osteoporosis</kwd>
<kwd>vitamin D</kwd>
<kwd>antiepileptic drugs</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>First reports on interference of antiepileptic drugs with calcium, phosphorus, and vitamin D metabolism emerged about 40 years ago in relation to phenytoin or phenobarbital therapy.<sup>
<xref ref-type="bibr" rid="bibr1-0883073812443005">1</xref>
</sup> Even though the complete mechanism is currently not understood, a general hypothesis is that the enzyme-inducing effect of these drugs also increases catabolism of 25-OH vitamin D by induction of hepatic microsomal enzymes that then causes osteoporosis or osteopenia.<sup>
<xref ref-type="bibr" rid="bibr2-0883073812443005">2</xref>
</sup> As a consequence, third-generation anticonvulsive drugs lacking this effect, such as gabapentin, should not interfere with bone metabolism. However, even though the risk seems to be particularly high in enzyme-inducing antiepileptic drugs as suggested by a recent study of female twins, there also might be a significant reduction in bone mineral density for non–enzyme-inducing antiepileptic drugs.<sup>
<xref ref-type="bibr" rid="bibr3-0883073812443005">3</xref>
</sup> This is supported by a recent study in a cohort of older community-dwelling men demonstrating a similar effect on bone metabolism for gabapentin compared with phenytoin and phenobarbital.<sup>
<xref ref-type="bibr" rid="bibr4-0883073812443005">4</xref>
</sup> Therefore, other factors have to be involved as for example a direct effect on osteoblast proliferation as suggested for phenytoin or impaired calcium absorption due to inhibition of calcitonin secretion.<sup>
<xref ref-type="bibr" rid="bibr5-0883073812443005">5</xref>,<xref ref-type="bibr" rid="bibr6-0883073812443005">6</xref>
</sup> Furthermore, other environmental and epidemiologic parameters have to be considered possibly influencing mineral metabolism like age, sex, or comorbidities like cerebral palsy. A recent study, for example, demonstrated marked fluctuation of 25-OH vitamin D concentrations over the year that clearly outweighed any medication effect.<sup>
<xref ref-type="bibr" rid="bibr7-0883073812443005">7</xref>
</sup>
</p>
<p>Interestingly, even though maximum bone mineral density is determined during childhood and later calcium supplementation in otherwise healthy individuals has only a minimal effect on bone mineral density and reduction of the risk for osteoporotic fractures, data on bone metabolism in children receiving antiepileptic drugs are scarce, with conflicting results. For instance, one study demonstrated an alteration of skeletal mineralization in children receiving carbamazepine or valproic acid even in the short term.<sup>
<xref ref-type="bibr" rid="bibr8-0883073812443005">8</xref>
</sup> Another study found only minimal effects on bone mineral metabolism in the same drugs.<sup>
<xref ref-type="bibr" rid="bibr9-0883073812443005">9</xref>
</sup> One more recent study demonstrated that children with epilepsy seem to sustain significant bone mineral density deficit compared with controls during the first 5 years of treatment that gradually worsens thereafter.<sup>
<xref ref-type="bibr" rid="bibr10-0883073812443005">10</xref>
</sup> However, because of the conception of the study, data on specific drugs were not available.</p>
<p>The aim of this study was to provide data on the influence of antiepileptic drugs on bone metabolism in a large cohort of otherwise healthy ambulatory children with epilepsy on chronic anticonvulsive monotherapy with particular focus on third-generation antiepileptic drugs like lamotrigine, oxcarbazepine, and levetiracetam. Specifically, we wanted to analyze the proportion of children with values of calcium or phosphorus below the third percentile and parathormone or alkaline phosphatase &gt;97th percentile and with values of 25-OH vitamin D below 10 ng/mL, respectively.</p>
<sec id="section1-0883073812443005" sec-type="methods">
<title>Methods</title>
<sec id="section2-0883073812443005">
<title>Participants and Study Design</title>
<p>This cross-sectional cohort study was conducted as a multicenter study from July 2007 to July 2011. Children between 1 and 18 years of age with epilepsy on monotherapy for at least 6 months with either valproic acid (&gt;10 mg/kg), oxcarbazepine (&gt;10 mg/kg), carbamazepine (&gt;10 mg/kg), lamotrigine (&gt;1 mg/kg), topiramate (&gt;1 mg/kg), sulthiame (&gt;3 mg/kg), or levetiracetam (&gt;15 mg/kg) were included. Exclusion criteria were acute or chronic disease affecting bone metabolism, immobility, lack of ambulatory gait, endocrinologic diseases, concomitant medication, or any other comorbidity like muscular dystrophy, other neurologic conditions, or recent osteomyelitis. Informed consent was obtained from all parents and if applicable also from the patients. Type of epilepsy at time of inclusion was defined according to the valid classification of the International League Against Epilepsy.<sup>
<xref ref-type="bibr" rid="bibr11-0883073812443005">11</xref>
</sup> The study was approved by the ethics committee of the Witten/Herdecke University and by the local ethics committees of the participating centers.</p>
</sec>
<sec id="section3-0883073812443005">
<title>Clinical Information, Anthropometry, and Blood Samples</title>
<p>Clinical information on type of epilepsy and duration of medication was retrieved from medical records. Additional relevant epidemiologic data were provided by the parents using a standardized questionnaire. Body mass index was calculated by the standard formula [body mass index = weight (kg)/height<sup>2</sup> (m)]. Blood sampling and all measurements were done in fasting state in the morning between 8 and 9 <sc>am</sc>.</p>
</sec>
<sec id="section4-0883073812443005">
<title>Assessment of Nutritional Calcium Intake</title>
<p>To assess mean calcium intake per patient per week, a standardized questionnaire was used, specifically asking among others for daily consumption of cheese, milk, and calcium-rich vegetables as well as for additional supplementation with vitamin D or calcium. Based on these data, patients were divided into quartiles. The upper quartile was defined as high, the middle 2 as medium, and the lower as low calcium intake. There is no routine enrichment of milk with vitamin D in Germany.</p>
</sec>
<sec id="section5-0883073812443005">
<title>Control Group</title>
<p>As control group for reference values, the results of the most recent German health survey with sex- and age-specific percentiles for alkaline phosphatase (7.299 boys, 6.956 girls), calcium (7.298 boys, 6.953 girls), phosphorus (7.294 boys, 6.944 girls), and 25-OH vitamin D (5.108 boys, 4.908 girls) were used.<sup>
<xref ref-type="bibr" rid="bibr12-0883073812443005">12</xref>
</sup>
</p>
</sec>
<sec id="section6-0883073812443005">
<title>Biochemical Analysis</title>
<p>Calcium, phosphorus, alkaline phosphatase, and parathormone were analyzed using COBAS 6000 CCE (Roche Diagnostics Deutschland; Mannheim, Germany) following standard procedures, and 25-OH vitamin D was determined using a specific radioimmunoassay (AC-35F1; Immunodiagnostic Systems Germany, IDS, Frankfurt, Germany).</p>
</sec>
<sec id="section7-0883073812443005">
<title>Statistics</title>
<p>Basic data were calculated as mean values with standard deviation and median values. Subgroup analysis included children receiving valproic acid, oxcarbazepine, and lamotrigine. Descriptive statistics were used for the proportion of children with values of calcium or phosphorus below the 3rd percentile and parathormone or alkaline phosphatase &gt;97th percentile compared with the control group and for the proportion of children with vitamin D deficiencies defined as 25-OH vitamin D values &lt;10 ng/mL. Hypocalcemia and hypophosphatemia were defined as concentrations below the third percentile of age-specific reference values. Testing for significant differences between groups was performed using 1-way analysis of variance (ANOVA) test followed by Bonferroni correction test for values with Gaussian distribution and the Mann-Whitney test for values without Gaussian distribution. The Kolmogorov-Smirnov test was used to rule out non-Gaussian distribution. Values for <italic>P</italic> &lt; .05 were considered statistically significant. All analyses were performed using GraphPad version 5.01 (La Jolla, California).</p>
</sec>
</sec>
<sec id="section8-0883073812443005">
<title>Results</title>
<sec id="section9-0883073812443005">
<title>Epidemiologic Characteristics</title>
<p>A total of 128 children (76 girls, 52 boys; mean age, 9 years 11 months ± 4 years 3 months; median, 9 years 7 months; range, 1 year 2 months to 17 years 4 months) were included in the study. All patients were white with German (n = 93), Turkish (n = 17), or Russian (n = 6) origin, and 12 coming from other European countries reflecting the normal population distribution in the regions of the participating centers. Fifty-six children were diagnosed with focal epilepsy (25 symptomatic, 22 cryptogenic, 9 idiopathic), 43 with generalized epilepsy (20 absence epilepsy, 23 other generalized epilepsies), and 5 had mixed epilepsies with generalized and focal signs. In the remaining 24 cases, no exact classification could be made on the basis of the available data.</p>
<p>Sixty-seven received valproic acid (mean dose, 22.3 mg/kg; range, 10-79 mg/kg), 26 were on oxcarbazepine (mean dose, 24.6 mg/kg; range,10-50 mg/kg), 14 on lamotrigine (mean dose, 4.4 mg/kg; range, 1.7-10 mg/kg), 11 on sulthiame (mean dose, 6.8 mg/kg; range, 4-10 mg/kg), 5 on levetiracetam (mean dose, 37.8 mg/kg; range, 15-55 mg/kg), 3 on carbamazepine, and 2 on topiramate, respectively. Length of anticonvulsive therapy varied from 6 months up to 13 years 2 months (mean, 30.8 ± 32.2 months; median, 19.5 months). Mean body mass index of all patients was 19.8 ± 4.7 kg/m<sup>2</sup> (median, 18.7 kg/m<sup>2</sup>; range, 12.4-43.3 kg/m<sup>2</sup>). There were no statistical significant differences of body mass index in relation to medication, dose, and duration of treatment.</p>
</sec>
<sec id="section10-0883073812443005">
<title>Effects of Anticonvulsive Therapy on Bone Metabolism</title>
<p>Mean concentrations of calcium were found to be significantly lower (<italic>P</italic> &lt; .01) among the whole study population (mean, 2.41 mmol/L) compared with data available from the German health survey cohort (mean, 2.53 mmol/L). Further subgroup analysis revealed significantly lower (<italic>P</italic> &lt; .01) mean calcium concentrations for patients treated with valproic acid (mean, 2.41 mmol/L), oxcarbazepine (mean, 2.39 mmol/L), and sulthiame (2.39 mmol/L), whereas patients treated with lamotrigine had concentrations within normal limits (mean, 2.48 mmol/L) (<xref ref-type="fig" rid="fig1-0883073812443005">Figure 1</xref>). Significant hypocalcemia was observed in 24.4% (n = 31 of 127) of patients (<xref ref-type="table" rid="table1-0883073812443005">Table 1</xref>). Analysis of inorganic phosphate, parathormone, and 25-OH vitamin D concentrations showed no significant differences for patients treated with valproic acid, oxcarbazepine, and sulthiame when compared with the German health survey cohort. However, mean concentrations for inorganic phosphate and parathormone tended to be lower in all patients on anticonvulsive medication (<xref ref-type="fig" rid="fig1-0883073812443005">Figure 1</xref>) corresponding to the observation that 25.4% of all patients (n = 30 of 118) had significant hypophosphatemia (<xref ref-type="table" rid="table1-0883073812443005">Table 1</xref>). Patients receiving lamotrigine also had normal concentrations of 25-OH vitamin D, but here concentrations of inorganic phosphate (mean, 1.35 vs 1.64 mmol/L) as well as parathormone (mean, 14.9 vs 39.5 ng/L) were significantly lower compared with the German health survey cohort. No statistically significant differences were noted between patients on different antiepileptic drugs medication for any of the analyzed laboratory parameters (<xref ref-type="fig" rid="fig1-0883073812443005">Figure 1</xref>). Also we did not detect any correlation between length of therapy and laboratory values.</p>
<fig id="fig1-0883073812443005" position="float">
<label>Figure 1.</label>
<caption>
<p>Laboratory values with respect to different drugs.</p>
</caption>
<graphic alternate-form-of="fig1-0883073812443005" xlink:href="10.1177_0883073812443005-fig1.tif"/>
</fig>
<table-wrap id="table1-0883073812443005" position="float">
<label>Table 1.</label>
<caption>
<p>Proportion of Abnormal Laboratory Values With Respect to Specific Drugs.</p>
</caption>
<graphic alternate-form-of="table1-0883073812443005" xlink:href="10.1177_0883073812443005-table1.tif"/>
<table>
<thead>
<tr>
<th> </th>
<th>All</th>
<th>Valproic Acid</th>
<th>Oxcarbazepine</th>
<th>Lamotrigine</th>
<th>Sulthiame</th>
<th>Levetiracetam</th>
<th>Carbamazepine</th>
<th>Topiramate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypocalcemia</td>
<td>31/127</td>
<td>15/67</td>
<td>7/25</td>
<td>1/14</td>
<td>5/11</td>
<td>2/5</td>
<td>0/3</td>
<td>0/2</td>
</tr>
<tr>
<td>Hypophosphatemia</td>
<td>30/118</td>
<td>16/60</td>
<td>2/25</td>
<td>6/13</td>
<td>4/11</td>
<td>0/4</td>
<td>1/3</td>
<td>1/2</td>
</tr>
<tr>
<td>25-OH-vitamin D deficiency</td>
<td>17/123</td>
<td>7/65</td>
<td>3/24</td>
<td>2/14</td>
<td>1/10</td>
<td>0/5</td>
<td>3/3</td>
<td>1/2</td>
</tr>
<tr>
<td>Elevated parathormone</td>
<td>5/120</td>
<td>2/64</td>
<td>3/24</td>
<td>0/14</td>
<td>0/10</td>
<td>0/4</td>
<td>0/2</td>
<td>0/2</td>
</tr>
<tr>
<td>Elevated alkaline phosphatase</td>
<td>5/125</td>
<td>1/66</td>
<td>2/26</td>
<td>1/13</td>
<td>0/11</td>
<td>0/5</td>
<td>1/2</td>
<td>0/2</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Even though mean 25-OH vitamin D concentrations were not different in patients on antiepileptic drugs compared with healthy controls, 13.3% of patients receiving anticonvulsive medication (n = 17) had significant vitamin D deficiency with 25-OH vitamin D values &lt;10 ng/mL (<xref ref-type="table" rid="table1-0883073812443005">Table 1</xref>). This seemed to particularly affect patients on carbamazepine therapy (n = 3) who all had levels of 25-OH vitamin D &lt; 10 ng/mL. There was no correlation between nutritional calcium intake and laboratory parameters for bone metabolism as shown in <xref ref-type="fig" rid="fig2-0883073812443005">Figure 2</xref>. In addition, in patients on valproic acid or oxcarbazepine therapy duration of therapy—comparing 6 to 12 to &gt;12 to 24 and &gt;24 months—had no effect on laboratory parameters of bone metabolism (<xref ref-type="fig" rid="fig3-0883073812443005">Figure 3</xref>). Such comparison was not available for patients treated with sulthiame, lamotrigine, topiramate, levetiracetam, or carbamazepine owing to the small number of cases in these groups.</p>
<fig id="fig2-0883073812443005" position="float">
<label>Figure 2.</label>
<caption>
<p>Laboratory values with respect to calcium intake.</p>
</caption>
<graphic alternate-form-of="fig2-0883073812443005" xlink:href="10.1177_0883073812443005-fig2.tif"/>
</fig>
<fig id="fig3-0883073812443005" position="float">
<label>Figure 3.</label>
<caption>
<p>Laboratory values with respect to duration of therapy.</p>
</caption>
<graphic alternate-form-of="fig3-0883073812443005" xlink:href="10.1177_0883073812443005-fig3.tif"/>
</fig>
</sec>
</sec>
<sec id="section11-0883073812443005">
<title>Discussion</title>
<p>Osteoporosis is one of the most important chronic clinical conditions affecting approximately 5% of the population and causing 1.5 million fractures in the United States annually.<sup>
<xref ref-type="bibr" rid="bibr13-0883073812443005">13</xref>
</sup> Patients receiving anticonvulsive drugs are considered as a high-risk group. After analyzing 4.521 patient-years and 185.066 seizures in institutionalized patients, there was a 4.3 × increased risk for all fractures and 3.2 × increased risk of fractures not related to fits in adults.<sup>
<xref ref-type="bibr" rid="bibr14-0883073812443005">14</xref>
</sup> A recent smaller study confirmed the elevation of risk of fractures also in children with epilepsy in a mixed pediatric population.<sup>
<xref ref-type="bibr" rid="bibr15-0883073812443005">15</xref>
</sup> However, it currently remains unclear whether this increased risk is due to the medication, the epilepsy itself, or other underlying comorbidities which are reflected by studies on phenytoin and valproic acid demonstrating negative effects on bone metabolism as well as no effects at all.<sup>
<xref ref-type="bibr" rid="bibr8-0883073812443005">8</xref>,<xref ref-type="bibr" rid="bibr9-0883073812443005">9</xref>,<xref ref-type="bibr" rid="bibr16-0883073812443005">16</xref>
<xref ref-type="bibr" rid="bibr17-0883073812443005"/>
<xref ref-type="bibr" rid="bibr18-0883073812443005"/>
<xref ref-type="bibr" rid="bibr19-0883073812443005"/>
<xref ref-type="bibr" rid="bibr20-0883073812443005"/>
<xref ref-type="bibr" rid="bibr21-0883073812443005"/>
<xref ref-type="bibr" rid="bibr22-0883073812443005"/>–<xref ref-type="bibr" rid="bibr23-0883073812443005">23</xref>
</sup> An extensive review of studies published until 2006 was given by Gissel.<sup>
<xref ref-type="bibr" rid="bibr24-0883073812443005">24</xref>
</sup>
</p>
<sec id="section12-0883073812443005">
<title>Valproic Acid and Carbamazepine</title>
<p>Concerning children on a monotherapy with valproic acid, we found hypocalcemia in 15 of 67 patients, hypophosphatemia in 16 of 60 and 25-OH vitamin D deficiency in 7 of 65, with an elevation of parathormone in 2 of 64 (<xref ref-type="table" rid="table1-0883073812443005">Table 1</xref>). This result is in accordance with some of the earlier studies focusing on bone mineral density. One study compared bone mineral density in 33 children receiving valproic acid for at least 6 months with 33 healthy children and found 7 osteopenic patients in the valproic acid group.<sup>
<xref ref-type="bibr" rid="bibr20-0883073812443005">20</xref>
</sup> Yet, 2 studies found a significant decrease of bone mineral density in children receiving valproic acid compared with healthy children but no changes in children receiving carbamazepine.<sup>
<xref ref-type="bibr" rid="bibr19-0883073812443005">19</xref>,<xref ref-type="bibr" rid="bibr21-0883073812443005">21</xref>
</sup>
</p>
<p>On the other hand, Akin et al found no differences comparing 25 children taking valproic acid and 28 children on carbamazepine for at least 1 year with 26 healthy controls.<sup>
<xref ref-type="bibr" rid="bibr17-0883073812443005">17</xref>
</sup> They also measured serum calcium, serum phosphorus, and alkaline phosphatase and failed to detect a significant difference like in a similar study in 36 children being treated with either valproic acid or carbamazepine for at least 1 year.<sup>
<xref ref-type="bibr" rid="bibr9-0883073812443005">9</xref>
</sup>
</p>
<p>One study followed 24 children on carbamazepine and 27 receiving valproic acid before start of medication and during the treatment for at least 1 year with regard to serum parameters like 25-OH vitamin D, parathormone, calcium, and phosphorus.<sup>
<xref ref-type="bibr" rid="bibr25-0883073812443005">25</xref>
</sup> Authors also included effects of seasonality on laboratory parameters and found a significant decrease of 25-OH vitamin D and an increase of parathormone in both drugs.</p>
<p>Another study with a similar design and comparable inclusion and exclusion criteria as in our investigation also included 85 children on valproic acid.<sup>
<xref ref-type="bibr" rid="bibr26-0883073812443005">26</xref>
</sup> There were higher body mass index, elevated leptin levels, and also higher levels of calcium and one marker of bone resorption in the group receiving valproic acid compared with children on other antiepileptic drugs. Speculatively, the diverging result in our study might be due to climatic conditions as this study was performed in a region with an annual average duration of sunshine of 1.800 hours compared with only 1.350 hours (Wuppertal, Düsseldorf) and 1.550 hours (Borna, Bamberg) in our study. However, in the study by Rauchenzauner et al, the proportion of children with vitamin D insufficiency (as defined by levels between 10 and 32 ng/mL) was higher in the epilepsy group compared with the control group (32% vs 15%), pointing in a similar direction as our results.<sup>
<xref ref-type="bibr" rid="bibr26-0883073812443005">26</xref>
</sup> Yet again, this does not clarify the difference to our control group because all participants share the same climatic environment.</p>
</sec>
<sec id="section13-0883073812443005">
<title>Modern Antiepileptic Drugs</title>
<p>In our study, we were able to demonstrate comparable findings in the “modern” antiepileptic drugs like oxcarbazepine and lamotrigine with a similar proportion of patients with hypocalcemia, hypophosphatemia, and 25-OH vitamin D deficiency as in the valproic acid group. There are few data if at all for these drugs. One study evaluated vitamin D levels and bone turnover in adult patients taking carbamazepine (n = 21) and oxcarbazepine (n = 24) in monotherapy and found comparable lower levels of 25-OH vitamin D in both groups compared with healthy controls.<sup>
<xref ref-type="bibr" rid="bibr27-0883073812443005">27</xref>
</sup> A recently published study in 166 children with a design comparable to that of our study did not find any child with vitamin D deficiency in children receiving oxcarbazepine (n = 17) or lamotrigine (n = 11).<sup>
<xref ref-type="bibr" rid="bibr26-0883073812443005">26</xref>
</sup> A study focusing on premenopausal women with epilepsy found significantly lower calcium concentrations in subjects receiving carbamazepine, phenytoin, and valproic acid than those on lamotrigine.<sup>
<xref ref-type="bibr" rid="bibr28-0883073812443005">28</xref>
</sup> Furthermore, other markers of bone turnover were not affected in patients taking lamotrigine. This is in accordance with our study, as in the subgroup analysis children on lamotrigine did not differ from the healthy control group. However, even after pooling all available data of the different studies on lamotrigine, the number of patients investigated is too small to rule out potential small influence on bone metabolism.</p>
</sec>
<sec id="section14-0883073812443005">
<title>Strengths and Limitations</title>
<p>The strengths of our study are the strict selection criteria with the exclusion of patients with lack of autonomous gait or other physical handicaps. This condition is considered one of the main risk factors because of other mechanisms like osteoporosis following inactivity, and some of the previous studies included up to 50% of patients with cerebral palsy and 28% being not able to walk at all.<sup>
<xref ref-type="bibr" rid="bibr29-0883073812443005">29</xref>
</sup> In addition, we included only patients on a monotherapy with the same drug at least for 6 months, ruling out that a recent change of medication might erroneously blame the wrong drug. These strict regulations were not applied in other studies where the exact time on the same drug was sometimes not provided in the data. Also the proportion of patients on polytherapy was up to 62%.<sup>
<xref ref-type="bibr" rid="bibr29-0883073812443005">29</xref>
</sup>
</p>
<p>Furthermore, our group is by now, except for 1 recently published study, 1 of the largest investigations in children receiving antiepileptic drug monotherapy. <sup>
<xref ref-type="bibr" rid="bibr26-0883073812443005">26</xref>
</sup>
</p>
<p>One limitation of our study is the lack of bone mineral density measurement. Bone mineral density is the best predictor of fracture risk with dual-energy x-ray absorptiometry considered the “gold standard.”<sup>
<xref ref-type="bibr" rid="bibr13-0883073812443005">13</xref>
</sup> However, as a result of the exposure to radiation, the risk-benefit analysis does not justify to perform bone mineral density measurement in all children on anticonvulsive medication, particularly from a parental point of view. We therefore chose blood serum markers as indicators for bone metabolism. Even if the debate is still going on considering the role of markers of bone turnover in clinical practice, most authors appreciate their value for clinical trials. In addition, for reasons of practicability and to improve recruitment, we did not perform serial measurements, for example, (1) before initiating the anticonvulsive drug, (2) after 12 months on the same drug, and/or (3) after stopping anticonvulsive therapy, but decided for a cross-sectional study.</p>
</sec>
</sec>
<sec id="section15-0883073812443005">
<title>Conclusion</title>
<p>In our opinion, the exact impact of antiepileptic drugs on bone mineral metabolism and bone mineral density is still unknown. Confounding factors like different sociocultural lifestyles, mixed pediatric and adult populations, different seasons, sun exposure, and geographic area in which the study was conducted must be taken into account when comparing different studies, with most of these variables hard to control. Nevertheless, we believe that the high proportion of hypocalcemia, hypophosphatemia, and 25-OH vitamin D deficiency in children receiving anticonvulsive medication justifies the assessment of bone mineral metabolism on a regular basis. At least children with proven vitamin D deficiency should receive a reasonable supplementation with vitamin D. With respect to yearly sun exposure, a general vitamin D supplementation might be discussed.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgment</title>
<p>The authors thank Gerhard Kluger (Epilepsy Center for Children and Adolescents, Vogtareuth), Heiner Hahn (Pediatric Department, Hospital Rotenburg), and Heike Nicolai (Pediatric Department, Klinikum Niederberg) for providing additional data.</p>
</ack>
<fn-group>
<fn fn-type="other" id="fn1-0883073812443005">
<label>Author Contributions</label>
<p>ACWJ, TL, and PB conceived and designed the study. PB, TL, MH, MK, UB collected data. PB, TL, ACWJ, and UB analyzed and interpreted the data. PB, ACWJ, and MK drafted the manuscript. ACWJ, MK, TL, and MH revised the manuscript for intellectual content. PB, TL, MH, MK, UB, and ACWJ approved the completed manuscript.</p>
</fn>
<fn fn-type="conflict" id="fn2-0883073812443005">
<label>Declaration of Conflicting Interests</label>
<p>The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Peter Borusiak has formerly received support from, has served as a speaker for, and taken part in investigations of Novartis, Janssen Cilag, UCB, Desitin, and Dibropharm. Ulrich Bettendorf has received support from UCB, Novartis, Desitin, Medice, and Allergan. The remaining authors and collaborators have no conflicts of interest. We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn3-0883073812443005">
<label>Funding</label>
<p>The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by a financial grant of the HELIOS Research Center [ID 1502].</p>
</fn>
<fn fn-type="other" id="fn4-0883073812443005">
<label>Ethical Approval</label>
<p>The study was approved by the ethic committee of the Witten/Herdecke University and by the local ethic committees of the participating centers.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0883073812443005">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dent</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Richens</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rowe</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Stamp</surname>
<given-names>TC</given-names>
</name>
</person-group>. <article-title>Osteomalacia with long-term anticonvulsant therapy in epilepsy</article-title>. <source>Br Med J</source>. <year>1970</year>;<volume>4</volume>:<fpage>69</fpage>–<lpage>72</lpage>.</citation>
</ref>
<ref id="bibr2-0883073812443005">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Farhat</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Yamout</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Mikati</surname>
<given-names>MA</given-names>
</name>
<etal/>
</person-group>. <article-title>Effect of antiepileptic drugs on bone density in ambulatory patients</article-title>. <source>Neurology</source>. <year>2002</year>;<volume>58</volume>:<fpage>1348</fpage>–<lpage>1353</lpage>.</citation>
</ref>
<ref id="bibr3-0883073812443005">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petty</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Paton</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>O'Brien</surname>
<given-names>TJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Effect of antiepileptic medication on bone mineral measures</article-title>. <source>Neurology</source>. <year>2005</year>;<volume>65</volume>:<fpage>1358</fpage>–<lpage>1365</lpage>.</citation>
</ref>
<ref id="bibr4-0883073812443005">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ensrud</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Walczak</surname>
<given-names>TS</given-names>
</name>
<name>
<surname>Blackwell</surname>
<given-names>TL</given-names>
</name>
<etal/>
</person-group>. <article-title>Antiepileptic drug use and rates of hip bone loss in older men: a prospective study</article-title>. <source>Neurology</source>. <year>2008</year>;<volume>71</volume>:<fpage>723</fpage>–<lpage>730</lpage>.</citation>
</ref>
<ref id="bibr5-0883073812443005">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feldkamp</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Witte</surname>
<given-names>OW</given-names>
</name>
<etal/>
</person-group>. <article-title>Long-term anticonvulsant therapy leads to low bone mineral density—evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells</article-title>. <source>Exp Clin Endocrinol Diabetes</source>. <year>2000</year>;<volume>108</volume>:<fpage>37</fpage>–<lpage>43</lpage>.</citation>
</ref>
<ref id="bibr6-0883073812443005">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fitzpatrick</surname>
<given-names>LA</given-names>
</name>
</person-group>. <article-title>Pathophysiology of bone loss in patients receiving anticonvulsant therapy</article-title>. <source>Epilepsy Behav</source>. <year>2004</year>;<volume>5</volume>:<fpage>3</fpage>–<lpage>15</lpage>.</citation>
</ref>
<ref id="bibr7-0883073812443005">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bacher</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kurth</surname>
<given-names>C</given-names>
</name>
</person-group>, <article-title>Steinhoff BJ. 25-Hydroxyvitamin-D-Spiegel bei antikonvulsiver Dauermedikation</article-title>. <source>Z Epileptol</source>. <year>2011</year>;<volume>24</volume>:<fpage>40</fpage>–<lpage>44</lpage>.</citation>
</ref>
<ref id="bibr8-0883073812443005">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kafali</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Erselcan</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tanzer</surname>
<given-names>F</given-names>
</name>
</person-group>. <article-title>Effect of antiepileptic drugs on bone mineral density in children between ages 6 and 12 years</article-title>. <source>Clin Pediatr. (Phila)</source> <year>1999</year>;<volume>38</volume>:<fpage>93</fpage>–<lpage>98</lpage>.</citation>
</ref>
<ref id="bibr9-0883073812443005">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Erbayat Altay</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Serdaroglu</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tumer</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Evaluation of bone mineral metabolism in children receiving carbamazepine and valproic acid</article-title>. <source>J Pediatr Endocrinol Metab</source>. <year>2000</year>;<volume>13</volume>:<fpage>933</fpage>–<lpage>999</lpage>.</citation>
</ref>
<ref id="bibr10-0883073812443005">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sheth</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Binkley</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Hermann</surname>
<given-names>BP</given-names>
</name>
</person-group>. <article-title>Progressive bone deficit in epilepsy</article-title>. <source>Neurology</source>. <year>2008</year>;<volume>70</volume>:<fpage>170</fpage>–<lpage>176</lpage>.</citation>
</ref>
<ref id="bibr11-0883073812443005">
<label>11</label>
<citation citation-type="journal">
<collab collab-type="author">Commission on Classification and Terminology of the International League Against Epilepsy</collab>. <article-title>Proposal for revised classification of epilepsies and epileptic syndromes</article-title>. <source>Epilepsia</source>. <year>1989</year>;<volume>30</volume>:<fpage>389</fpage>–<lpage>399</lpage>.</citation>
</ref>
<ref id="bibr12-0883073812443005">
<label>12</label>
<citation citation-type="web">
<person-group person-group-type="author">
<name>
<surname>Dortschy</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Schaffrath Rosario</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Scheidt-Nave</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Bevölkerungsbezogene Verteilungswerte ausgewählter Laborparameter aus der Studie zur Gesundheit von Kindern und Jugendlichen in Deutschland (KiGGS)</article-title>. <comment>Robert Koch-Institut, Berlin 2009. Available at</comment>: <ext-link ext-link-type="uri" xlink:href="http://www.kiggs.de/experten/downloads/dokumente/KiGGS_Laborparameter[1].pdf">http://www.kiggs.de/experten/downloads/dokumente/KiGGS_Laborparameter[1].pdf</ext-link>. <comment>Accessed December 15, 2011</comment>.</citation>
</ref>
<ref id="bibr13-0883073812443005">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elliot</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Binkley</surname>
<given-names>N</given-names>
</name>
</person-group>. <article-title>Evaluation and measurement of bone mass</article-title>. <source>Epilepsy Behav</source>. <year>2004</year>;<volume>5</volume>:<fpage>16</fpage>–<lpage>23</lpage>.</citation>
</ref>
<ref id="bibr14-0883073812443005">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Desai</surname>
<given-names>KB</given-names>
</name>
<name>
<surname>Ribbans</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>GJ</given-names>
</name>
</person-group>. <article-title>Incidence of five common fracture types in an institutional epileptic population</article-title>. <source>Injury</source>. <year>1996</year>;<volume>27</volume>:<fpage>97</fpage>–<lpage>100</lpage>.</citation>
</ref>
<ref id="bibr15-0883073812443005">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gniatkowska-Nowakowska</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Fractures in epilepsy children</article-title>. <source>Seizure</source>. <year>2010</year>;<volume>19</volume>:<fpage>324</fpage>–<lpage>325</lpage>.</citation>
</ref>
<ref id="bibr16-0883073812443005">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chung</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ahn</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Effects of anti-epileptic drug therapy on bone mineral density in ambulatory epileptic children</article-title>. <source>Brain Dev</source>. <year>1994</year>;<volume>16</volume>:<fpage>382</fpage>–<lpage>385</lpage>.</citation>
</ref>
<ref id="bibr17-0883073812443005">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akin</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Okutan</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Sarrici</surname>
<given-names>Ü</given-names>
</name>
<etal/>
</person-group>. <article-title>Evaluation of bone mineral density in children receiving antiepileptic drugs</article-title>. <source>Pediatr Neurol</source>. <year>1998</year>;<volume>19</volume>:<fpage>129</fpage>–<lpage>131</lpage>.</citation>
</ref>
<ref id="bibr18-0883073812443005">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>CY</given-names>
</name>
<name>
<surname>Ronen</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Atkinson</surname>
<given-names>SA</given-names>
</name>
</person-group>. <article-title>Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy</article-title>. <source>Epilepsia</source>. <year>2001</year>;<volume>42</volume>:<fpage>1141</fpage>–<lpage>1147</lpage>.</citation>
</ref>
<ref id="bibr19-0883073812443005">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ecevit</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Aydoğan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kavakli</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Altinöz</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Effect of carbamazepine and valproate on bone mineral density</article-title>. <source>Pediatr Neurol</source>. <year>2004</year>;<volume>31</volume>:<fpage>279</fpage>–<lpage>282</lpage>.</citation>
</ref>
<ref id="bibr20-0883073812443005">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oner</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kaya</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Karasalihoğlu</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Bone mineral metabolism changes in epileptic children receiving valproic acid</article-title>. <source>J Paediatr Child Health</source>. <year>2004</year>;<volume>40</volume>:<fpage>470</fpage>–<lpage>473</lpage>.</citation>
</ref>
<ref id="bibr21-0883073812443005">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sheth</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Wesolowski</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Jacob</surname>
<given-names>JC</given-names>
</name>
<etal/>
</person-group>. <article-title>Effect of carbamazepine and valproate on bone mineral density</article-title>. <source>J Pediatr</source>. <year>1995</year>;<volume>127</volume>:<fpage>256</fpage>–<lpage>262</lpage>.</citation>
</ref>
<ref id="bibr22-0883073812443005">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rieger-Wettengl</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Tutlewski</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Stabrey</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Analysis of the musculoskeletal system in children and adolescents receiving anticonvulsant monotherapy with valproic acid or carbamazepine</article-title>. <source>Pediatrics</source>. <year>2001</year>;<volume>108</volume>:<fpage>E107</fpage>.</citation>
</ref>
<ref id="bibr23-0883073812443005">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tekgul</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Serdaroglu</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Huseyinov</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gökben</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Bone mineral status in pediatric outpatients on antiepileptic drug monotherapy</article-title>. <source>J Child Neurol</source>. <year>2006</year>;<volume>21</volume>:<fpage>411</fpage>–<lpage>414</lpage>.</citation>
</ref>
<ref id="bibr24-0883073812443005">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gissel</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Poulsen</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Vestergaard</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Adverse effects of antiepileptic drugs on bone mineral density in children</article-title>. <source>Expert Opin Drug Saf</source>. <year>2007</year>;<volume>6</volume>:<fpage>267</fpage>–<lpage>278</lpage>.</citation>
</ref>
<ref id="bibr25-0883073812443005">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nicolaidou</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Georgouli</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kotsalis</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Effects of anticonvulsant therapy on vitamin D status in children: prospective monitoring study</article-title>. <source>J Child Neurol</source>. <year>2006</year>;<volume>21</volume>:<fpage>205</fpage>–<lpage>209</lpage>.</citation>
</ref>
<ref id="bibr26-0883073812443005">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rauchenzauner</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Griesmacher</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tatarczyk</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Chronic antiepileptic monotherapy, bone metabolism, and body composition in non-institutionalized children</article-title>. <source>Dev Med Child Neurol</source>. <year>2010</year>;<volume>52</volume>:<fpage>283</fpage>–<lpage>288</lpage>.</citation>
</ref>
<ref id="bibr27-0883073812443005">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mintzer</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Boppana</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Toguri</surname>
<given-names>J</given-names>
</name>
<name>
<surname>DeSantis</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine</article-title>. <source>Epilepsia</source>. <year>2006</year>;<volume>47</volume>:<fpage>510</fpage>–<lpage>515</lpage>.</citation>
</ref>
<ref id="bibr28-0883073812443005">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pack</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Morrell</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Marcus</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy</article-title>. <source>Ann Neurol</source>. <year>2005</year>;<volume>57</volume>:<fpage>252</fpage>–<lpage>257</lpage>.</citation>
</ref>
<ref id="bibr29-0883073812443005">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coppola</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Fortunato</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Auricchio</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Bone mineral density in children, adolescents, and young adults with epilepsy</article-title>. <source>Epilepsia</source>. <year>2009</year>;<volume>50</volume>:<fpage>2140</fpage>–<lpage>2146</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>